Research Site
Seoul, South Korea
18,727 recruiting
Showing 1–20 of 295 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
B-cell Malignancies
AstraZeneca174 enrolled30 locationsNCT06542250
Recruiting
Phase 1
A Study of AZD0120 in Autoimmune Diseases
Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort
Gynaecological cancers
AstraZeneca350 enrolled1 locationNCT07101081
Recruiting
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
AsthmaChronic Rhinosinusitis With Nasal Polyps (CRSwNP)
AstraZeneca110 enrolled9 locationsNCT07399665
Recruiting
Phase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
Asthma
AstraZeneca440 enrolled135 locationsNCT06307665
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled301 locationsNCT06692738
Recruiting
Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
Healthy ParticipantsDyslipidemia
AstraZeneca136 enrolled6 locationsNCT06980428
Recruiting
Phase 1Phase 2
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
Prostate Cancer
AstraZeneca300 enrolled18 locationsNCT07336446
Recruiting
Phase 1Phase 2
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
Staphylococcus Aureus
AstraZeneca231 enrolled42 locationsNCT06749457
Recruiting
DESTINY-PANTUMOUR04
Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting
Phase 1Phase 2
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Advanced or Metastatic Non-small Cell Lung Cancer
AstraZeneca152 enrolled104 locationsNCT06996782
Recruiting
Phase 1
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Endometrial CancerColorectal CarcinomaNon-small Cell Lung Cancer+3 more
AstraZeneca108 enrolled18 locationsNCT06218914
Recruiting
The Eplontersen Pregnancy and Lactation Outcomes Study
Transthyretin Amyloidosis
AstraZeneca10 enrolled1 locationNCT07205666
Recruiting
Phase 1Phase 2
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled80 locationsNCT06137118
Recruiting
OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain
Non-small Cell Lung Cancer
AstraZeneca500 enrolled25 locationsNCT06068049
Recruiting
Phase 3
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Locally Advanced Cervical Cancer
AstraZeneca800 enrolled204 locationsNCT06079671
Recruiting
Phase 1
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Solid TumorsClear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.362 enrolled25 locationsNCT05536141
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
Asthma
AstraZeneca231 enrolled143 locationsNCT06023589
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer
AstraZeneca625 enrolled316 locationsNCT06103864
Recruiting
Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled111 locationsNCT07391657